|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date13 Mar 2007 |
卡培他滨加奥沙利铂联合或不联合拉帕替尼,用于ErbB2阳性的晚期胃癌或食道癌或胃食道结合部腺癌的III期研究
[Translation] A phase III study of capecitabine plus oxaliplatin with or without lapatinib in patients with ErbB2-positive advanced gastric or esophageal cancer or gastroesophageal junction adenocarcinoma
本研究的主要目的是比较卡培他滨加奥沙利铂,即CapeOx方案联合拉帕替尼对比CapeOx方案联合安慰剂治疗,患者的总体生存期获益
[Translation] The primary objective of this study was to compare the overall survival benefit of patients treated with capecitabine plus oxaliplatin (CapeOx plus lapatinib) versus CapeOx plus placebo.
100 Clinical Results associated with SmithKline Beecham (Cork) Ltd.
0 Patents (Medical) associated with SmithKline Beecham (Cork) Ltd.
100 Deals associated with SmithKline Beecham (Cork) Ltd.
100 Translational Medicine associated with SmithKline Beecham (Cork) Ltd.